Literature DB >> 17990157

Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy.

Christoph Beglinger1, Jean Dudler, Christian Mottet, Laurent Nicod, Frank Seibold, Peter M Villiger, Jean-Pierre Zellweger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17990157     DOI： 2007/43/smw-11939

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN： 0036-7672            Impact factor:   2.193


× No keyword cloud information.
  22 in total

1.  [Serious course of a miliary tuberculosis in a 34-year-old patient with ulcerative colitis and HIV infection under concomitant therapy with infliximab].

Authors:  Jonas Zeitz; Milo Huber; Gerhard Rogler
Journal:  Med Klin (Munich)       Date:  2010-04

2.  Negative effect of immunosuppressive therapy in the performance of the QuantiFERON gold in-tube test in patients with immune-mediated inflammatory diseases.

Authors:  José M Ramos; Mar Masiá; Juan C Rodríguez; Cristina López; Sergio Padilla; Catalina Robledano; Francisco J Navarro-Blasco; Jaime Matarredona; Mariana F García-Sepulcre; Félix Gutiérrez
Journal:  Clin Exp Med       Date:  2012-06-27       Impact factor: 3.984

Review 3.  Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy.

Authors:  Kevin L Winthrop; Michael Iseman
Journal:  Nat Rev Rheumatol       Date:  2013-06-25       Impact factor: 20.543

Review 4.  Preventing and treating biologic-associated opportunistic infections.

Authors:  Kevin L Winthrop; Tom Chiller
Journal:  Nat Rev Rheumatol       Date:  2009-07       Impact factor: 20.543

5.  Diagnosis of latent tuberculosis infection with T-SPOT(®).TB in a predominantly immigrant population with rheumatologic disorders.

Authors:  Patricio Escalante; Kirstin J Kooda; Rizwana Khan; San San Aye; Stratos Christianakis; Daniel G Arkfeld; Glenn R Ehresmann; Jens J Kort; Brenda E Jones
Journal:  Lung       Date:  2014-10-16       Impact factor: 2.584

Review 6.  Interferon γ-release assays for detecting latent tuberculosis infection in patients scheduled for anti-TNFα therapy.

Authors:  Kay Greveson; Charlie Murray; Christos Toumpanakis; Owen Epstein; Mark Hamilton; Marc Lipman
Journal:  Frontline Gastroenterol       Date:  2010-11-20

7.  Interferon-γ release assay in the diagnosis of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea.

Authors:  Boksoon Chang; Hye Yun Park; Kyeongman Jeon; Joong Kyong Ahn; Hoon-Suk Cha; Eun-Mi Koh; Eun-Suk Kang; Won-Jung Koh
Journal:  Clin Rheumatol       Date:  2011-05-10       Impact factor: 2.980

8.  Is it safe to use anti-TNF-α agents for tuberculosis in children suffering with chronic rheumatic disease?

Authors:  Omer Kilic; Ozgur Kasapcopur; Yildiz Camcioglu; Haluk Cokugras; Nil Arisoy; Necla Akcakaya
Journal:  Rheumatol Int       Date:  2011-07-26       Impact factor: 2.631

9.  Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy.

Authors:  Dimitrios Vassilopoulos; Stamatoula Tsikrika; Chrisoula Hatzara; Varvara Podia; Anna Kandili; Nikolaos Stamoulis; Emilia Hadziyannis
Journal:  Clin Vaccine Immunol       Date:  2011-10-12

Review 10.  Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy.

Authors:  Kevin L Winthrop; Eric Chang; Shellie Yamashita; Michael F Iademarco; Philip A LoBue
Journal:  Emerg Infect Dis       Date:  2009-10       Impact factor: 6.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.